Esperion settles patent dispute with Dr. Reddy's over cholesterol drugs
Source: SeekingAlpha
2025-10-03 10:49:58 ET
More on Esperion Therapeutics, Dr. Reddy's
- Esperion: A Mixture Of Opportunity And Risk: Why I Would Hold For Now
- Esperion Therapeutics, Inc. (ESPR) Presents At Cantor Global Healthcare Conference 2025 Transcript
- Esperion Therapeutics, Inc. 2025 Q2 - Results - Earnings Call Presentation
- SA Asks: How could higher India tariffs impact drug stocks?
- Esperion rises after revenue beat, Q1 profitability expectation
Read the full article on Seeking Alpha
For further details see:
Esperion settles patent dispute with Dr. Reddy’s over cholesterol drugs
Esperion Therapeutics Inc.
NASDAQ: ESPR
ESPR Trading
-0.21% G/L:
$2.425 Last:
2,420,621 Volume:
$2.56 Open:
ESPR Latest News
March 10, 2026 06:00:00 am
Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
ESPR Stock Data
$804,448,466
234,999,359
0.16%
70
N/A
Pharmaceuticals
Healthcare
US
Ann Arbor
